Background: Continuing care following inpatient addiction treatment is an important component in the continuum of clinical services. Mutual help, including 12-step groups like Alcoholics Anonymous, is often recommended as a form of continuing care. However, the effectiveness of 12-step groups is difficult to establish using observational studies due to the risks of selection bias (or confounding).

Objective: To address this limitation, we used both conventional and machine learning-based propensity score (PS) methods to examine the effectiveness of 12-step group involvement following inpatient treatment on substance use over a 12-month period.

Methods: Using data from the Recovery Journey Project - a longitudinal, observational study - we followed an inpatient sample over 12-months post-treatment to assess the effect of 12-step involvement on substance use at 12-months (n = 254). Specifically, PS models were constructed based on 34 unbalanced confounders and four PS-based methods were applied: matching, inverse probability weighting (IPW), doubly robust (DR) with matching, and DR with IPW.

Results: Each PS-based method minimized the potential of confounding from unbalanced variables and demonstrated a significant effect (p <  0.001) between high 12-step involvement (i.e., defined as having a home group; having a sponsor; attending at least one meeting per week; and, being involved in service work) and a reduced likelihood of using substances over the 12-month period (odds ratios 0.11 to 0.32).

Conclusions: PS-based methods effectively reduced potential confounding influences and provided robust evidence of a significant effect. Nonetheless, results should be considered in light of the relatively high attrition rate, potentially limiting their generalizability.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2021.108943DOI Listing

Publication Analysis

Top Keywords

effectiveness 12-step
12
conventional machine
8
propensity score
8
score methods
8
methods examine
8
examine effectiveness
8
12-step group
8
group involvement
8
involvement inpatient
8
inpatient addiction
8

Similar Publications

Background: Following the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).

Method: This was a retrospective review (2013-2022) of patients with immediate HSRs to biological agents.

View Article and Find Full Text PDF

Levels and outcomes of 12-step participation among sexual and gender minority subgroups.

J Subst Use Addict Treat

December 2024

The PRIDE Study/PRIDEnet, Stanford University School of Medicine, United States of America; Department of Community Health Systems, School of Nursing, University of California, San Francisco, United States of America; Alliance Health Project, Department of Psychiatry, School of Medicine, University of California, San Francisco, United States of America.

Introduction: Sexual minority (e.g., bisexual, gay, lesbian, queer) and gender minority (e.

View Article and Find Full Text PDF

Introduction: Taxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients.

View Article and Find Full Text PDF

Off-Label Use of Lamotrigine and Naltrexone in the Treatment of Ketamine Use Disorder: A Case Report.

J Addict Med

August 2024

From the David Geffen School of Medicine at UCLA, Los Angeles, CA (TA); Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA (FV); UCLA Semel Institute, Los Angeles, CA (RM); Department of Psychiatry and Biobehavioral Science, UCLA, Los Angeles, CA (IM); and Department of Emergency Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA (EAS).

Article Synopsis
  • Ketamine is increasingly used in the U.S. for mental health treatment but its nonmedical use and resulting disorder (KUD) are not well-studied domestically, despite rising prevalence.
  • A case study of a 32-year-old man with KUD showed that after traditional treatment, he experienced severe cravings and was treated with lamotrigine and naltrexone, which reduced his cravings and altered his ketamine experience.
  • The treatment highlights a potential strategy for KUD, combining pharmacotherapy and therapeutic support, but further research is necessary to understand its effectiveness.
View Article and Find Full Text PDF

Introduction: Medications for opioid use disorders (MOUD) remain the gold standard for treating OUD, but treatment initiation and adherence remain challenging. Exclusive utilization of pharmacotherapy as a treatment modality for OUD is sub-optimal, and a combination of psychotherapies and pharmacotherapies is recommended. General trends indicate the benefits of peer mentoring and MBRP separately.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!